SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors anticipate potential catalysts from the upcoming earnings call, with community chatter focused on a possible buyout or partnership announcement, especially with AstraZeneca, given their aligned earnings release date and recent facilities transaction. Some traders are positioning for a short squeeze due to high short interest and a decrease in available shares to borrow, while others express skepticism and frustration with management's past performance. The broader context involves speculation around the future of COVID-19 vaccines and Novavax's role in the evolving market.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending amid excitement surrounding a new partnership with Perplexity AI, which includes a $400 million deal and integration of AI search into Snapchat. The community is discussing the potential for this deal, combined with a stock buyback program, to signal a turnaround and re-rate the stock, especially given Snap's large user base and AI initiatives. Some traders are anticipating a short squeeze and upgrades from analysts.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors anticipate upcoming earnings, with many expecting a positive report driven by strong growth and the Alani Nu acquisition. The community is actively discussing potential price targets and whether the stock will experience a post-earnings surge, while also debating the impact of potential market manipulation. Sentiment remains largely bullish, with some viewing any dips as buying opportunities ahead of earnings.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT) is trending as the community debates its potential amid discussions of buybacks and token unlocks scheduled for February. Some investors express concerns about competitor influence, particularly from $BNB and $ASTER, while others champion $AVNT as a Coinbase-backed project with a live buyback dashboard and locked developer tokens. Traders are watching key price levels, anticipating volatility and potential for a short squeeze.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending due to a significant after-hours drop following its earnings release, despite reporting a revenue and EPS beat. Community chatter revolves around the disappointing forward guidance and concerns about future growth, leading to debates about valuation and the potential impact of AI on its business model. Some investors view the dip as a buying opportunity, while others express caution amid analyst downgrades.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending as the EV maker announced partnerships with both Uber and Nvidia, generating bullish sentiment. The community is discussing the potential for Lucid to achieve Level 4 autonomous driving and the possibility of a short squeeze. Despite the positive news, concerns remain around profitability, upcoming earnings, and potential dilution.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending as investors discuss the company's potential in AI-driven infrastructure and smart city solutions, fueled by significant contracts and growing institutional confidence. Community members highlight the favorable risk-reward asymmetry and upcoming earnings as potential catalysts. Some traders express frustration with recent price action, while others remain optimistic about the long-term prospects and potential acquisition.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as the community anticipates a potential breakout, emphasizing its long-term potential. Many users are highlighting the ability to earn crypto through walking and staking, though others are wary of the token's price action. Community members are also excited about the US launch of Sweat Wallet.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending as investors assess the impact of recent earnings and guidance, with debates focusing on long-term profitability and growth potential. Community members are weighing the company's AI integration and potential for a short squeeze against concerns about valuation and lock-up periods. The stock's performance relative to peers and broader market trends is also a key talking point.

SSgA Active Trust - Financial Select Sector SPDR

Financial Select Sector SPDR Fund

XLF is trending amid discussions about potential breakouts and pullbacks, as well as reaction to bank stress test results. Community members are actively trading options, with bullish and bearish sentiment around the fund's next move. Economic indicators and sector rotation are also influencing conversations around XLF.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to shareholders. If you...

Shares of Exicure Inc. surged more than 25% on Thursday, reaching levels last seen over three weeks ago, following the announcement of a strategic acquisition and collaboration deal with South Korea-based GPCR Therapeutics.Exicure revealed it has agreed to purchase all shares of GPCR Therapeutics USA, the California-based subsidiary of GPCR Therapeutics.&nbsp;As part of the agreement, Exicure and GPCR have entered into a licensing and collaboration arrangement to advance and commercialize GPCR-related technologies.While financial terms of the acquisition were not disclosed, Exicure outlined that the deal includes milestone payments to GPCR Therapeutics tied to clinical trial progress, marketing approvals, and net sales achievements.&nbsp;Additionally, Exicure will pay a recurring royalty of at least 10% of net sales derived from the licensed technologies.Retail interest surged after the announcement, with Exicure’s message volume on Stocktwits spiking, placing the ticker among the top 10 trending symbols on the platform.<stembedurl>https://stocktwits.com/topstockalerts/message/601124689</stembedurl><stembedurl>https://stocktwits.com/Pippi_Langstrumpf66/message/601121735</stembedurl>GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.&nbsp;The company is also behind Yervoy, the first FDA-approved treatment for lung cancer.&nbsp;Currently, GPCR USA is conducting a Phase 2 clinical trial targeting blood cancer patients, focusing on those requiring hematopoietic stem cell transplantation (HSCT) for conditions like multiple myeloma.Exicure’s stock has been a standout performer, gaining 265% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes 

GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.

Equity

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. (Nasdaq: XCUR, the Company, Exicure), today announced that on January 19, 2025, Exicure Inc. (the Company) entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean...

Micro-cap early-stage biotech Exicure, Inc.’s ($XCUR) shares rose sharply in premarket trading on Friday following a deal to acquire a cancer drug pipeline from a South Korean company.The company announcement late Thursday that it had signed a memorandum of understanding with GPCR Therapeutics on Dec. 24 to acquire the latter’s US subsidiary. The agreement also provides for technology transfer and collaborative research on GPCR’s other ongoing drug development pipelines.Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, which is in Phase 2 development, along with its related patents and intellectual property.&nbsp;The company views the proposed acquisition as a means to advance as a clinical-stage biotech. It plans to finalize the ongoing clinical trials involving stem cell mobilizers in multiple myeloma patients and prepare clinical studies related to acute myeloid leukemia.&nbsp;Excurire said the market potential for the two blood cancer types is around $1 billion to $2 billion annually.The company also plans to collaborate on R&amp;D in GPCR’s ongoing research in immuno-oncology, fibrosis treatments, and obesity therapies.&nbsp;South Korean drug company GPCR specializes in GPCR (G Protein-Coupled Receptor), representing over one-third of all drug targets. The company has secured target patents around prominent GPCRs such as CXCR4. It possesses multiple pipelines addressing blood cancers and solid tumors, genetic disorders, idiopathic pulmonary fibrosis, and obesity, including ongoing Phase 2 trials in the U.S. for multiple myeloma.&nbsp;Exicure said the deal will be funded from the $14 million capital investments it recently secured in three transactions.&nbsp;In an 8-K filing with the SEC, Exicure said the Nasdaq has notified that the company has met all requirements for continued listing on the exchange.A Stocktwits watcher pointed to the stock's low float and predicted a sharp move on the news.<stembedurl>https://stocktwits.com/SBW_Trades/message/597953319</stembedurl>In premarket trading, Exicure stock was up 8.41% at $18.70 at 7:05 a.m.ET. The stock has gained nearly 500% for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/5-media-and-entertainment-and-communication-services-stocks-that-gained-massive-retail-following-on-stocktwits-in-2024/cJO7BR7RjM">5 Media &amp; Entertainment And Communication Services Stocks That Gained Massive Retail Following On Stocktwits in 2024</a>

Woman examining laboratory samples - stock photo | Image source: Getty Images

Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Nasdaq Compliance: Retail Exuberant

Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, along with its related patents and intellectual property. 

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Exicure, Inc. (Nasdaq: XCUR, Exicure, the Company), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. (GPCR Therapeutics) on December 24, 2024, aimed at...

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. (Nasdaq: XCUR, the Company, Exicure), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders...

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR, the 'Company') has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated...

Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket

Exicure Stock Is Soaring After The Bell: What's Driving The Action?

Shares of low-float micro-cap stock Exicure are rocketing higher in Wednesday's after-hours session after the company announced that it received an extension from the Nasdaq Hearings Panel.
read more...

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Exicure, Inc. (Exicure or the Company) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (Panel) granted an extension to continue...

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

XCUR
Exicure Inc

Feed

News

Sentiment

Fundamentals

Info

Latest XCUR News

XCURExicure Inc